Trial Profile
An Open-Label, Single-Arm, Multi-Center, Phase II Study of Troxatyl (Troxacitabine) Administered by Continuous Infusion in Patients With Acute Myeloid Leukemia (AML) in Second Salvage
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 02 Jun 2011
Price :
$35
*
At a glance
- Drugs Troxacitabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 31 Oct 2005 New trial record.